NCT06877676 2026-02-13
Pre-Approval Expanded Access Study for TAR-200 Treating Physician Use
Janssen Research & Development, LLC
Approved for marketing
Clinical Trials
11 trialsNCT05401214 2025-06-13
Pre-approval Access Single Patient Request for Niraparib / Abiraterone Acetate Combination (Nira/AA Combination)
Janssen Research & Development, LLC
Approved for marketing
NCT04100694 2025-05-20
Early Access Program Providing HER2/HER3 Bispecific Antibody, MCLA-128, for a Patient With Advanced NRG1-Fusion Positive Solid Tumor
Merus B.V.
Approved for marketing
NCT04809584 2024-12-19
18F-DCFPyL PET/MRI in Regional Nodal&Distant Metastases Detection in Intermediate &HR Prostate Cancer
Stanford University
Approved for marketing
NCT04452136 2022-03-14
Expanded Access Protocol of 68Ga PSMA 11 PET Imaging of Prostate Cancer
OHSU Knight Cancer Institute
Approved for marketing
NCT04348682 2021-06-24
Expanded Access Protocol of 68Ga-PSMA-11 for PET Imaging
Jonsson Comprehensive Cancer Center
Approved for marketing
NCT04377152 2021-03-01
Expanded Access 68Gallium-PSMA-11 PET for Prostate Cancer
University of California, San Francisco
Approved for marketing
NCT04136808 2020-01-13
An Expanded Access Treatment Protocol of Enfortumab Vedotin in Subjects With Locally Advanced or Metastatic Urothelial Carcinoma
Astellas Pharma Inc
Approved for marketing
NCT01217697 2017-03-24
Study of Abiraterone Acetate in Patients With Advanced Prostate Cancer
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Approved for marketing
NCT02355054 2017-01-20
Detecting Recurrent Prostate Cancer With C-11 Choline Positron Emission Tomography: An Expanded Access Study
Washington University School of Medicine
Approved for marketing
NCT02589717 2016-11-02
An Expanded Access Study of Atezolizumab in Participants With Locally Advanced or Metastatic Urothelial Carcinoma After Failure With Platinum-Containing Chemotherapy
Genentech, Inc.
Approved for marketing